PriMera Scientific Surgical Research and Practice
Volume 4 Issue 6 December 2024
DOI: 10.56831/PSSRP-04-153
ISSN: 2836-0028

PriMera Scientific Publications

Harnessing Multifunctional Nanosponges for Precision Colon Drug Delivery: A Synergistic Approach to Therapeutics and Microbiome Modulation

Type: Review Article
Received: October 30, 2024
Published: November 26, 2024

Citation:
R Vinoth. "Harnessing Multifunctional Nanosponges for Precision Colon Drug Delivery: A Synergistic Approach to Therapeutics and Microbiome Modulation". PriMera Scientific Surgical Research and Practice 4.6 (2024): 21-29.

R Vinoth*

Department of Pharmaceutics, Thanthai Roever College of Pharmacy, Tamilnadu, India

***Corresponding Author:** R. Vinoth, Assistant Professor, Thanthai Roever College of Pharmacy, Perambalur, Tamilnadu, India.

Abstract

Colon-targeted drug delivery systems are crucial for effectively treating diseases such as inflammatory bowel disease, colorectal cancer, and irritable bowel syndrome. The challenges of premature drug degradation in the upper gastrointestinal tract and poor site specificity hinder optimal therapeutic outcomes. Moreover, dysbiosis of gut microbiota complicates these conditions, necessitating therapies that not only deliver medications but also restore microbial balance. Nanosponges have emerged as innovative carriers that address these challenges by providing protection against degradation, enabling site-specific release in response to colonic stimuli, and allowing for dual-action therapies that combine drug delivery with microbiome modulation. This review discusses the various mechanisms through which nanosponges function, including pH-responsive, enzyme-responsive, and microbiota-responsive designs. Furthermore, the potential of nanosponges to co-deliver therapeutic agents and probiotics or prebiotics is explored, highlighting their role in restoring gut health while effectively treating colonic disorders. With advances in personalization and combination therapies, nanosponges hold promise for revolutionizing colon drug delivery and improving patient outcomes.

Keywords: colon drug delivery system; nanosponges; microbiomes; probiotics; personalized medicines

Introduction

Colon-targeted drug delivery is essential for treating a range of diseases including inflammatory bowel disease (IBD), colorectal cancer (CRC), and irritable bowel syndrome (IBS). Localized therapy is often necessary for specific diseases in order to reduce systemic adverse effects and enhance medication effectiveness [1]. However, there are a number of important obstacles that the current colon drug delivery systems (CDDS) must overcome. One significant obstacle is the early degradation of medications in the upper gastrointestinal (GI) tract, where they may be broken down by digestive enzymes or stomach acid, reducing the quantity that makes it to the colon. Poor site specificity is another problem, when medications meant for the colon are delivered too soon, resulting in less than ideal therapeutic outcomes. The gut microbiota, an ecology of billions of bacteria that are essential to both health and sickness, makes the colon a special place.

A number of colonic disorders, including IBD and colorectal cancer, have been connected to dysbiosis, or an imbalance in the microbiota. Consequently, there is growing interest in treatments that might alter the microbiota in addition to administering medications in order to restore equilibrium and enhance the course of disease [2]. However, delivering microbiome-modulating agents like probiotics or prebiotics to the colon without degradation in the upper GI tract remains a challenge.

Nanosponges indicate a significant advance in surmounting these obstacles. These very porous, nanoscale carriers may safeguard pharmaceuticals against degradation during transit through the gastrointestinal system and guarantee that therapeutic substances are released exclusively upon reaching the colon [3]. Nanosponges may be designed to react to certain stimuli found in the colon, such variations in pH, the presence of enzymes, or interactions with gut bacteria. This facilitates precise and regulated medication delivery, enhancing the effectiveness of therapies for illnesses such as IBD and CRC. Furthermore, nanosponges provide the capability for multimodal treatment by transporting both pharmaceuticals and microbiome-modulating substances [4]. This dual-action potential might treat not only the inflammatory and malignant problems in the colon but also the underlying microbial imbalances that frequently lead to these disorders. As a consequence, nanosponges are not only increasing medication delivery but also giving new possibilities in customized medicine, where therapies may be tailored to particular patient requirements, including their distinct microbiota composition. However multifunctional nanosponges offer a novel platform for colon-targeted medication administration. They provide protection against premature drug degradation, regulated release in response to colonic-specific cues, and the capacity to modify the gut microbiome, treating both the illness and the microbiota imbalances associated with it. These improvements establish nanosponges as a huge leap forward in the treatment of colonic disorders, providing more effective, targeted, and customized treatments.

Nanosponges as Carriers for Colon Drug Delivery

Overview of Nanosponges

Nanosponges have emerged as very adaptable carriers in the realm of drug delivery, with their unique structure and functional plasticity permitting both protective and targeted release mechanisms. The Figure.1 provides the detailed mechanisms for nanosponges in drug delivery system. Nanosponges are very porous, nano-scale structures often manufactured from biocompatible polymers such as cyclodextrins or hyper-crosslinked polypeptides. Their unusual shape enables them to encapsulate a wide variety of medicines, including both hydrophilic and hydrophobic compounds [5]. In CDDS, nanosponges are especially helpful owing to their capacity to protect sensitive drugs from the severe environment of the stomach and small intestine, delivering them intact to the colon.

Role in Targeted Colon Drug Delivery

Nanosponges must be able to identify and react to the particular environmental conditions of the colon in order to work there efficiently. The unique characteristics of the colon, including its alkaline pH, enzymatic activity from the colonic microbiota, and particular microbial metabolites, have led to the development of a number of site-specific release mechanisms.

pH-Responsive Nanosponges

The pH of the colon is neutral to slightly alkaline, in contrast to the stomach's acidic environment. Typically, pH-responsive nanosponges are covered with substances like Eudragit® or pH-sensitive polysaccharides (like pectin or alginate) that breakdown in the alkaline environment of the colon but stay stable in the acidic upper GI tract [6]. Targeting medications to the colon, where the coating breaks down and the encapsulated medication is delivered straight to the target location, is made possible by this pH-triggered release mechanism.

Enzyme-Responsive Nanosponges

Numerous region-specific enzymes, including azoreductases, glycosidases, and nitro reductases, are produced by the intestinal microbiota. Only when colonic enzymes are present may the breakdown of the carrier and subsequent medication release be facilitated by coating nanosponges with polysaccharides or linkers that are sensitive to these enzymes [7]. Anti-inflammatory medications used to treat IBD benefit greatly from this enzyme-triggered release, which is extremely specific to the colon and guarantees that the medication stays encapsulated until it reaches the target region.

Microbiota Responsive Nanosponges

Colon-targeted nanosponges have recently been developed with designs that specifically interact with certain metabolites or bacterial species found in the gut microbiome. In the presence of certain bacteria that are known to be more common in sick or dysbiotic colons, or in reaction to metabolites like short-chain fatty acids (SCFAs), microbiota-responsive nanosponges may be functionalized to breakdown. This customized method enables the nanosponge to adjust to each person's own microbiota composition, which may lead to better treatment results for diseases including IBD and colorectal cancer (CRC) [8].



Figure 1: Nanosponges in drug delivery systems.

Drug Delivery and Microbiome Modulation in colon

Nanosponges offer a promising approach to dual-action therapy, where they serve not only as carriers for drugs but also as vehicles for microbiome-modulating agents. By delivering both therapeutic drugs and microbiome modulators, such as probiotics, prebiotics, or microbiota-targeted compounds, nanosponges provide a comprehensive treatment strategy that addresses both the disease pathology and underlying dysbiosis.

Co-Delivery of Therapeutic Agents and Probiotics

In conditions like IBD and CRC, restoring microbiota balance alongside drug therapy may enhance therapeutic efficacy. Nanosponges can encapsulate probiotics alongside anti-inflammatory or anti-cancer agents, protecting them from the acidic stomach environment and delivering them intact to the colon. This combined approach allows for simultaneous therapeutic action on inflammation or tumors and microbiome restoration, which is essential in preventing disease recurrence and improving gut health [9].

Targeted Delivery of Prebiotics and Metabolite Modulators

Prebiotics, compounds that promote the growth of beneficial bacteria, can also be co-delivered with drugs using nanosponges. Additionally, nanosponges can be designed to release metabolites that encourage the production of anti-inflammatory short-chain fatty acids (SCFAs) by beneficial bacteria [10]. This two-fold action creates an environment that not only treats the primary disease but also supports a healthier microbiome, potentially reducing inflammation and preventing future dysbiosis-related conditions.

Multifunctional Role of Nanosponges in Microbiome Modulation

Nanosponges as Probiotic Delivery Vehicles

Probiotics and medicinal medications may be encapsulated in nanosponges to shield them from the stomach's acidic environment and guarantee that they reach the colon, where they can start to work. When probiotics and anti-inflammatory or anti-cancer medications are taken together, the gut microbial balance is restored and the illness is treated. This might improve therapeutic results [11].

The Gut Microbiome and Colon Health

A varied population of bacteria living in the colon, the gut microbiome is essential to preserving the health and equilibrium of the gastrointestinal tract. Numerous colonic disorders, such as irritable bowel syndrome (IBS), colorectal cancer, and IBD, have been connected to dysbiosis, or an imbalance in the microbiota [12]. Using medication delivery technologies to alter the microbiota is a viable strategy for therapeutic treatments in these illnesses.

Combined Therapy: Drugs and Microbiome Modulators

Recent studies have investigated the co-administration of microbiome modulators, such as probiotics or prebiotics, and therapeutic agents, including anti-inflammatory medications. It is possible to create nanosponges that release these elements in concert, fostering the restoration of the microbiota as well as direct therapeutic benefits. In conditions like IBD, where inflammation and microbiota imbalance are important considerations, this combination may be very beneficial [13].

Delivery of Prebiotics to Support Beneficial Bacteria

Nanosponges may also include prebiotics, which are indigestible fibers that encourage the development of good bacteria. These prebiotics are released by the nanosponges when they enter the colon, improving the environment for good bacteria and encouraging the synthesis of SCFAs (short-chain fatty acids like butyrate) [14]. Lowering inflammation and preserving a balanced microbiome, may stop the return of illness.

Release of Bacterial Metabolite Modulators

By interacting with the microbiota, metabolites or their precursors may be loaded onto nanosponges to promote the synthesis of advantageous substances like SCFAs. For example, it is possible to encapsulate and distribute butyrate, a well-known anti-inflammatory SCFA, straight to the colon [15]. As an alternative, substances released by nanosponges may stimulate the production of SCFAs by resident bacteria, which promote the integrity of the epithelial barrier and aid in immune response modulation.

The Positive Impact of Nanosponges

Nanosponges are spherical, very porous structures that are often made of biocompatible polymers like hyper-crosslinked polypeptides or cyclodextrins. Because of their unique shape, which provides high surface area and encapsulation effectiveness, they may transport a variety of therapeutic molecules, including hydrophilic and hydrophobic substances.



Figure 2: Nanosponges in treatment of colon based diseases.

High Drug-Loading Capacity and Stability

In comparison to traditional carriers, In nanosponges, sponge-like, porous structure offers significant interior space, enabling the encapsulation of several therapeutic agents or greater drug concentrations. When it comes to colon medication delivery, where substantial amounts of anti-inflammatory, chemotherapeutic, or microbiome-modulating drugs may be needed, this high loading capacity is very helpful. Furthermore, a higher proportion of the medication reaches the colon undamaged because nanosponges protect it from enzymatic breakdown in the small intestine or early deterioration in the stomach's acidic medium.

Controlled and Targeted Release Potential

Nanosponges may be designed to release their contents in response to certain stimuli, such as pH variations, the presence of enzymes, or interactions with the microbiota in the colon. By ensuring that medications are precisely delivered to the colon's site of action, this regulated, targeted release capacity minimizes systemic exposure and minimizes negative effects. Nanosponges improve the therapeutic window and bioavailability of medications by preserving a constant release profile, guaranteeing continuous drug activity that is crucial for long-term illnesses like inflammatory bowel disease (IBD).

Protection of Drug Molecules During Transit

Drugs intended for colon delivery often degrade in the acidic environment of the stomach or get broken down by enzymes in the small intestine. Nanosponges provide a protective barrier around these drugs, safeguarding them from harsh conditions in the upper GI tract and ensuring they remain stable until they reach the colon. It results in Increased drug stability ensures a higher percentage of the therapeutic agent reaches the target site, leading to more consistent and reliable treatment outcomes [16].

Reduction in Systemic Side Effects

Targeted release reduces medication breakdown in the upper gastrointestinal tract, assuring stability and lowering the requirement for large dosages that might induce systemic toxicity. Nanosponges also provide precise, localized drug delivery, which eliminates the need for systemic drug administration. In chronic conditions including inflammatory bowel disease and colorectal cancer, nanosponges' regulated, sustained release helps to maintain effective medication concentrations in the colon over time. To further reduce systemic exposure, they also enable combination therapy, such as combining probiotics with anti-inflammatory medications at lower dosages. By minimizing side effects typical of oral or systemic medication delivery, nanosponges improve treatment adherence, decrease immunological suppression, and increase patient safety by limiting off-target effects. Long-term treatment is safer and more bearable thanks to nanosponges, which effectively and patient-friendly manage colonic disorders with fewer hazards by keeping medications isolated to the colon.

Challenges in Nanosponges for Colon Drug Delivery

Stability During GI Transit

To reach the colon, nanosponges must preserve their dimensional stability while traveling through the small intestine, which is rich in enzymes, and the stomach's acidic environment. The nanosponges may become unstable when exposed to stomach acids and digestive enzymes, which might result in an early release of the medication. Because of this early release, less medication reaches the colon, which lowers the effectiveness of treatment. The target-specific advantages of nanosponge-based delivery methods may also be jeopardized if the medication is absorbed in unexpected areas of the GI tract, leading to systemic adverse effects [17].

Controlled and Targeted Release

There are differences in the pH and microbiota profiles of each colon, making it difficult to guarantee that nanosponges release their therapeutic payload only in the colon. Nanosponges' reactivity is impacted by this variability, which may result in erratic drug release rates. If the medicine is given too soon, inconsistent release patterns may result in systemic dispersion or subtherapeutic levels reaching the colon. For illnesses that target the colon, this unpredictability may affect treatment results and decrease the efficacy of nanosponge therapy.

Interaction with the Colonic Microbiome

Although individual microbiome compositions vary greatly, nanosponges often depend on microbial enzymes in the colon to initiate medication release. Patients may respond differently to treatment as a result of this variance if the medication release mechanism is not consistently activated. Furthermore, extended exposure to nanosponges may change bacterial populations in the microbiome, which raises the possibility of unanticipated disruptions. It is challenging to get consistent therapy effects across various patient microbiomes because of these issues.

Drug Loading and Encapsulation Efficiency

The quantity of medicine that nanosponges can transport is restricted by their small internal capacity, which might be problematic for medications that need significant dosages to work. Additionally, drug instability inside the structure may result from incompatibilities between certain medications and nanosponge polymers, which may lower encapsulation effectiveness. Insufficient medication concentrations in the colon may result from low loading and encapsulation, requiring larger dosages or more frequent administration, which may raise expenses and increase the risk of adverse effects.

Safety and Biocompatibility Concerns

It is essential to make sure that nanosponges are biocompatible in the delicate intestinal environment. Certain polymeric substances may cause the colon to become inflamed or irritated by stimulating immune responses or breaking down into hazardous metabolites. If prolonged usage of nanosponges disrupts the microbiota or interferes with the sensitive colonic mucosa, it may potentially have an effect on gut health. The use of nanosponges in chronic therapies, where long-term compatibility is crucial, is restricted by safety issues such as these [18].

Scalability and Cost of Production

The manufacturing method for nanosponges is complicated and needs careful control over polymer synthesis, drug encapsulation, and particle size, making scaling problematic. High production costs owing to specific materials and manufacturing procedures further affect affordability. This price barrier restricts the accessibility of nanosponge-based therapeutics for larger clinical applications, especially if cost-effective alternatives are accessible.

Future Prospects: Personalized Medicine and Patient-Specific Nanosponges

Advanced Targeting Mechanisms

Advanced targeting methods that allow nanosponges to react precisely to physiological changes in the colon, including pH fluctuations or microbial activity, may be included in the future. By improving drug localization, this targeting accuracy may guarantee that therapeutic medicines are released exactly where they are required. By reducing systemic exposure and adverse effects, such advancements may enhance the effectiveness of therapies for a range of colonic illnesses.

Personalized Medicine Approaches

Nanosponges may be customized to match the microbiome profiles of specific patients as our understanding of the microbiome grows. Drug release might be optimized by customization based on the distinct enzyme activity in each patient's gut [19]. Treatment results for diseases like colorectal cancer (CRC) and inflammatory bowel disease (IBD) may be greatly enhanced by tailoring nanosponges for certain microbial habitats.

Integration with Combination Therapies

Combination therapy might benefit greatly from the use of nanosponges, which enable the loading of many medications into a single formulation. By concurrently addressing many disease pathways and lowering the likelihood of medication resistance, this strategy may improve treatment results. Combination treatments administered by nanosponges may provide enhanced effectiveness for complicated diseases like cancer by synchronizing medication release characteristics.

Nanosponges in Gene Therapy

Moreover, nanosponges have shown potential as delivery systems for gene treatments that target hereditary illnesses that impact the colon. These devices may open up new treatment options for genetically driven colonic disorders like familial adenomatous polyposis by delivering sensitive nucleic acids straight to the colon while shielding them from deterioration.

Improved Biocompatibility and Safety Profiles

To increase the safety of nanosponges, research will concentrate on creating biocompatible and biodegradable materials. By making sure that degradation products are non-toxic, these developments will reduce the possibility of negative side effects from prolonged usage. In order to improve patient adherence and results, enhanced biocompatibility will be essential for chronic illnesses that call for continuous medication.

Innovative Manufacturing Techniques

It is anticipated that developments in manufacturing technologies, such as microfluidics and 3D printing, would simplify the process of creating nanosponges. These methods may guarantee consistent quality across batches, lower expenses, and increase scalability. Nanosponge-based treatments will probably become more accessible and available for a wider range of therapeutic applications as manufacturing techniques grow more economical.

Expanded Applications Beyond the Colon

The concepts of nanosponges may be applied to various therapeutic regions, such as targeted medication administration in the upper gastrointestinal system and beyond, despite their primary emphasis on colon drug delivery. This adaptability may allow for new uses in the treatment of diverse illnesses, offering creative answers in a range of medical specialties. Nanosponges may develop into an essential tool for tackling a variety of therapeutic issues as research advances.

Enhanced Monitoring and Feedback Mechanisms

Smart technology may be included into nanosponges to allow for real-time medication delivery and colonic status monitoring in near future. Sensors that provide patients and medical professionals feedback might be one example of such an invention, allowing for prompt therapeutic modifications. Improved patient adherence and the general efficacy of drug delivery systems would result from this capacity, which would also maximize therapeutic results and improve individualized treatment programs.

Conclusion

The use of nanosponges offers a revolutionary solution for a number of colon issues, including colorectal cancer (CRC), inflammatory bowel disease (IBD), and other gastrointestinal ailments. By enabling localized medication release that reduces systemic adverse effects and increases treatment effectiveness, these cutting-edge delivery methods complement targeted therapy. Enhancing treatment efficacy may be achieved by integrating sophisticated targeting mechanisms and customizing nanosponges to react to distinct microbiome profiles. The adaptability of nanosponges is further increased as research advances via the incorporation of combination treatments and the investigation of broader uses beyond the colon. Future developments will probably concentrate on resolving present issues like stability and biocompatibility while putting in place precise legal frameworks to enable the effective and safe use of these technologies. All things considered, nanosponges have a bright future in colon medication delivery, with the potential to transform therapeutic modalities and enhance patient outcomes in the treatment of illnesses relating to the colon.

References

1. A Kumar., et al. "Nanomedicine for colon-targeted drug delivery: strategies focusing on inflammatory bowel disease and colon cancer". Nanomedicine (London, England) 19.15 (2024): 1347-1368.
2. A Gazzaniga., et al. "Time-Based Formulation Strategies for Colon Drug Delivery". Pharmaceutics 14.12 (2022): 2762-2762.
3. Atheer Awad., et al. "Clinical translation of advanced colonic drug delivery technologies". Advanced Drug Delivery Reviews (2021): 114076-114076.
4. Guy Van den Mooter and Van den Mooter G. "Colon drug delivery". Expert Opinion on Drug Delivery 3.1 (2006): 111-25.
5. Enas Alkhader., et al. "Mucoadhesive Chitosan-Pectinate Nanoparticles for the Delivery of Curcumin to the Colon". Aaps Pharmscitech 18.4 (2017): 1009-18.
6. Felipe Varum., et al. "A dual pH and microbiota-triggered coating (PhloralTM) for fail-safe colonic drug release". International Journal of Pharmaceutics 583 (2020): 119379.
7. Kun Feng., et al. "Colon-targeted delivery systems for nutraceuticals: A review of current vehicles, evaluation methods and future prospects". Trends in Food Science and Technology 102 (2020): 203-22.
8. Kulbacka J., et al. "Curcumin Loaded Nanocarriers with Varying Charges Augmented with Electroporation Designed for Colon Cancer Therapy". International Journal of Molecular Sciences 23.3 (2022): 1377-1377.
9. Libo Yang., et al. "Colon-specific drug delivery: new approaches and in vitro/in vivo evaluation". International Journal of Pharmaceutics 235.1 (2002): 1-15.
10. Seth Amidon., et al. "Colon-targeted oral drug delivery systems: design trends and approaches". Aaps Pharmscitech 16.4 (2015): 731-41.
11. Susan Hua., et al. "Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: selective targeting to diseased versus healthy tissue". Nanomedicine: Nanotechnology, Biology and Medicine 11.5 (2015): 1117-32.

12. K Praveen and K Balamurugan. "Targeted Drug Delivery through Nanosponges and its Approach". Research Journal of Pharmacy and Technology 13.7 (2020): 3524-9.
13. R. Rajam and Kavin Raj Muthukumar. "An Updated Comprehensive Review on Nanosponges - Novel Emerging Drug Delivery System". Research Journal of Pharmacy and Technology 14.8 (2021): 4476-84.
14. Nitish., et al. "A Review on Nanosponges - A Promising Novel Drug Delivery System". Research Journal of Pharmacy and Technology 14.1 (2021): 501-5.
15. P Farsana., et al. "Hydrogel based Nanosponges drug delivery for topical applications - A updated review". Research Journal of Pharmacy and Technology 14.1 (2021): 527-30.
16. Janani Sadhasivam, Abimanyu Sugumaran and Damodharan Narayanaswamy. "Nano Sponges: A Potential Drug Delivery Approach". Research Journal of Pharmacy and Technology 13.7 (2020): 3442-8.
17. Selvamuthukumar S., et al. "Nanosponges: a novel class of drug delivery system—review". Journal of Pharmacy and Pharmaceutical Sciences 15.1 (2012): 103-11.
18. Saliha Moutaharrik., et al. "In vitro and in vivo evaluation of a pH-, microbiota- and time-based oral delivery platform for colonic release". Eur J Pharm Biopharm 183 (2023): 13-23.
19. María Plaza-Oliver, Manuel Jesús Santander-Ortega and María Victoria Lozano. "Current approaches in lipid-based nanocarriers for oral drug delivery". Drug Delivery and Translational Research 11.2 (2021): 471-97.